Process Controllers and Analyzers
Medchemexpress LLC Ars-1630 | 1698055-86-5 | 430.84 | 50 MG
ARS-1630 is a less active enantiomer of ARS-1620, identified as a novel inhibitor of mutant K-ras G12C. It is intended for research use only.
- Solid appearance
- Color ranges from white to yellow
- Soluble in DMSO at ≥ 100 mg/mL
- Inhibits mutant K-ras G12C by targeting Cys-12
- Requires active cycling of KRASG12C between active-GTP and inactive-GDP conformations
HANNAS PHARMACEUTICAL SUPPLY CO INC 10CC L LOCK SYRNG WITH 41 VNT
NC2607648 10CC L LOCK SYRNG WITH 41 VNT
Med Vet International Jorvet Metal Frame, for 10cc Henke Roux Syringe, J0053D27B
Replacement Metal Frame for Jorvet 10cc Henke Roux Syringe.
Med Vet International Jorvet Compression Plunger, for 10cc Hauptner Syringe, J0031D09A
Replacement Compression plunger for the Jorvet 10cc Hauptner syringe.
Med Vet International Jorvet Outer Rod for 10cc Hauptner Syringe, J0031D11A
Replacement outer rod for Jorvet 10cc Hauptner syringe.
Med Vet International Jorvet Inner Rod, for 10cc Henke Roux Syringe, J0053D28B
Replacement Inner Rod for Jorvet 10cc Henke Roux Syringe.
Selleck Chemical LLC ARS-1323-E1856-5MG
ARS-1323 is the racemic mixture containing ARS-1620 and a potent inhibitor of mutant KRAS G12C It can be used in research for biochemical binding screens as companion imaging drugs (CID) for KRAS G12C
Selleck Chemical LLC ARS-1323-E1856-100MG
ARS-1323 is the racemic mixture containing ARS-1620 and a potent inhibitor of mutant KRAS G12C It can be used in research for biochemical binding screens as companion imaging drugs (CID) for KRAS G12C
Medchemexpress LLC Ars-1630 | 1698055-86-5 | 430.84 | 10 MG
This compound is a novel inhibitor of mutant K-ras G12C, derived from patent WO 2015054572 A1. It is intended for research use only and not for patient administration.
- Inhibitor of mutant K-ras G12C.
- Utilizes allele-specific covalent targeting of Cys-12.
- Targets an inducible allosteric switch II pocket.
- Requires active cycling between active-GTP and inactive-GDP conformations for targeting.
- Demonstrates feasibility for inhibiting mutant KRAS in laboratory settings.
- High purity (98.10%).